Inhibitor Therapeutics, Inc.
INTI
$0.0514
-$0.0086-14.33%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 20.85% | 42.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 82.51% | 38.98% | |||
| Operating Income | -82.51% | -38.98% | |||
| Income Before Tax | -94.50% | -45.70% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -94.50% | -45.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -94.50% | -45.70% | |||
| EBIT | -82.51% | -38.98% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -97.62% | -44.83% | |||
| Normalized Basic EPS | -92.59% | -50.00% | |||
| EPS Diluted | -97.62% | -44.83% | |||
| Normalized Diluted EPS | -92.59% | -50.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
